119-hr4573

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4573 Introduced in House

    (IH) ]

<DOC>

119th CONGRESS
 1st Session
 H. R. 4573

To amend the Internal Revenue Code of 1986 to provide a credit to small 
businesses for research activities related to the mitigation of certain 
 drug threats.

_______________________________________________________________________

 IN THE HOUSE OF REPRESENTATIVES

 July 21, 2025

 Mr. Neguse (for himself, Mr. Ciscomani, Ms. Dean of Pennsylvania, Mr. 
Bacon, Ms. Dexter, and Mr. Lawler) introduced the following bill; which 
 was referred to the Committee on Ways and Means

_______________________________________________________________________

 A BILL

To amend the Internal Revenue Code of 1986 to provide a credit to small 
businesses for research activities related to the mitigation of certain 
 drug threats.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Innovate to Save Lives Act''.

SEC. 2. CREDIT FOR RESEARCH ACTIVITIES OF SMALL BUSINESSES RELATED TO 
 THE MITIGATION OF CERTAIN DRUG THREATS.

    (a) In General.--

Section 41

    (a) of the Internal Revenue Code of 1986 
is amended by striking ``and'' at the end of paragraph

    (2) , by striking 
the period at the end of paragraph

    (3) and inserting ``, and'', and by 
adding at the end the following new paragraph:
 ``

    (4) in the case of a small business (as defined in 
 subsection

    (b)

    (3)
            (D) 
            (iii) ), 10 percent of the qualified drug 
 threat mitigation research expenses (as defined in subsection
            (i) ) for the taxable year.''.

    (b) 

=== Definitions. ===
-

Section 41 of such Code is amended by adding at 
the end the following new subsection:
 ``
            (i) Qualified Drug Threat Mitigation Research Expenses.--For 
purposes of this section--
 ``

    (1) Qualified drug threat mitigation research expenses.--
 The term `qualified drug threat mitigation research expenses' 
 means the qualified research expenses which would be determined 
 under subsection

    (b) if `qualified drug threat mitigation 
 research' were substituted for `qualified research' each place 
 it appears therein.
 ``

    (2) Qualified drug threat mitigation research.--The term 
 `qualified drug threat mitigation research' means qualified 
 research which is undertaken for the purpose of discovering 
 information related to mitigating or treating the effects of 
 the use of a specified drug or to preventing, diverting, or 
 intervening in such use. Such term shall not include any 
 clinical research unless such research complies with the 
 policies and guidelines of the National Institutes of Health 
 for clinical research.
 ``

    (3) Specified drug.--
 ``
        (A) In general.--The term `specified drug' means 
 any emerging drug, fentanyl, fentanyl-related 
 substance, or methamphetamine.
 ``
        (B) Emerging drug.--The term `emerging drug' 
 means a drug designated as an emerging drug threat 
 under 

section 709
            (c) of the Office of National Drug 
 Control Policy Reauthorization Act of 1998 (21 U.S.C. 
 1708
            (c) ). Such term shall include any such drug for any 
 taxable year if such designation is in effect under 
 such section at any time during such taxable year.
 ``
            (C) Fentanyl-related substance.--The term 
 `fentanyl-related substance' means any substance that 
 is structurally related to fentanyl by 1 or more of the 
 following modifications:
 ``
            (i) By replacement of the phenyl portion 
 of the phenethyl group by any monocycle, 
 whether or not further substituted in or on the 
 monocycle.
 ``
            (ii) By substitution in or on the 
 phenethyl group with alkyl, alkenyl, alkoxyl, 
 hydroxyl, halo, haloalkyl, amino, or nitro 
 groups.
 ``
            (iii) By substitution in or on the 
 piperidine ring with alkyl, alkenyl, alkoxyl, 
 ester, ether, hydroxyl, halo, haloalkyl, amino, 
 or nitro groups.
 ``
            (iv) By replacement of the aniline ring 
 with any aromatic monocycle whether or not 
 further substituted in or on the aromatic 
 monocycle.
 ``
            (v) By replacement of the N-propionyl 
 group with another acyl group.''.
            (c) Effective Date.--The amendments made by this section shall 
apply to taxable years beginning after the date of the enactment of 
this Act.
            (d) GAO Report.--5 years after the date of the enactment of this 
Act, the Comptroller General shall submit a written report to Congress 
regarding the amount of tax credits allowed under 

section 41

    (a)

    (4) of 
the Internal Revenue Code of 1986 for qualified drug threat mitigation 
expenses and the types of qualified drug threat mitigation research 
with respect to which such credits were allowed. The Comptroller 
General shall ensure that the data in such report is anonymous and that 
any studies undertaken to prepare such report do not impede qualified 
drug threat mitigation research.
 <all>